The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: Vasoconstrictor and structural mechanisms contribute equally

Experimental Physiology

Volumn 97, Issue 6, 2012, Pages 796-806

  Cahill, Edwina ^a   Rowan, Simon C ^a   Sands, Michelle ^a   Banahan, Mark ^a   Ryan, Donal ^b   Howell, Katherine ^a   McLoughlin, Paul ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; Y 27635;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC HYPOXIC PULMONARY HYPERTENSION; CONTROLLED STUDY; ENZYME INHIBITION; HYPOXIA; LUNG VASCULAR RESISTANCE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; VASOCONSTRICTION; Y27635;

EID: 84862594477     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.065474     Document Type: Article

References (52)

1. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K & Shimokawa H (2006). Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 48, 280-285.
2. Alexander AF, Will DH, Grover RF & Reeves JT (1960). Pulmonary hypertention and right ventricular hypertrophy in cattle at high altitude. Am J Vet Res 21, 199-204.
3. Anand IS, Harris E, Ferrari R, Pearce P & Harris P (1986). Pulmonary haemodynamics of the yak, cattle, and cross breeds at high altitude. Thorax 41, 696-700.
4. Banchero N, Grover RF & Will JA (1971). High altitude-induced pulmonary arterial hypertension in the llama (Lama glama). Am J Physiol 220, 422-427.
5. Berkov S (1974). Hypoxic pulmonary vasoconstriction in the rat: the necessary role of angiotensin II. Circ Res 35, 256-261.
6. Cadogan E, Hopkins N, Giles S, Bannigan JG, Moynihan J & McLoughlin P (1999). Enhanced expression of inducible nitric oxide synthase without vasodilator effect in chronically infected lungs. Am J Physiol Lung Cell Mol Physiol 277, L616-L627.
7. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W & Schermuly RT (2010). Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 36, 808-818.
8. Deem S, Kim JU, Manjula BN, Acharya AS, Kerr ME, Patel RP, Gladwin MT & Swenson ER (2002). Effects of S-nitrosation and cross-linking of hemoglobin on hypoxic pulmonary vasoconstriction in isolated rat lungs. Circ Res 91, 626-632.
9. Deem S, Swenson ER, Alberts MK, Hedges RG & Bishop MJ (1998). Red-blood-cell augmentation of hypoxic pulmonary vasoconstriction: hematocrit dependence and the importance of nitric oxide. Am J Respir Crit Care Med 157, 1181-1186.
10. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG & McMurtry IF (2004). Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287, L656-L664.
11. Feihl F, Liaudet L, Levy BI & Waeber B (2008). Hypertension and microvascular remodelling. Cardiovasc Res 78, 274-285.
12. Fishman AP (1985). Pulmonary circulation. In American Handbook of Physiology, vol. 1. ed. Fishman AP & Fisher AB, pp. 93-165. American Physiological Society, Bethesda, Maryland, USA.
13. Ge RL, Kubo K, Kobayashi T, Sekiguchi M & Honda T (1998). Blunted hypoxic pulmonary vasoconstrictive response in the rodent Ochotona curzoniae (pika) at high altitude. Am J Physiol Heart Circ Physiol 274, H1792-H1799.
14. Grover RF, Wagner WW, McMurtry IF & Reeves JT (1983). Pulmonary circulation. In The Cardiovascular System, vol. 3. ed. Shepard JT & Aboud FM, pp. 103-136. American Physiological Society, Bethesda, Maryland, USA.
15. Groves BM, Reeves JT, Sutton JR, Wagner PD, Cymerman A, Malconian MK, Rock PB, Young PM & Houston CS (1987). Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol 63, 521-530.
16. Gupta ML, Rao KS, Anand IS, Banerjee AK & Boparai MS (1992). Lack of smooth muscle in the small pulmonary arteries of the native Ladakhi. Is the Himalayan highlander adapted? Am Rev Respir Dis 145, 1201-1204.
17. Herget J & McMurtry IF (1987). Dexamethasone potentiates hypoxic vasoconstriction in salt solution-perfused rat lungs. Am J Physiol Heart Circ Physiol 253, H574-H581.
18. Hopkins N & McLoughlin P (2002). The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat 201, 335-348.
19. Howell K, Costello CM, Sands M, Dooley I & McLoughlin P (2009). l-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 296, L1042-L1050.
20. Howell K, Preston RJ & McLoughlin P (2003). Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol 547, 133-145.
21. Hsia CC, Hyde DM, Ochs M & Weibel ER (2010). An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 181, 394-418.
22. Hyvelin J-M, Howell K, Nichol A, Costello CM, Preston RJ & McLoughlin P (2005). Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97, 185-191.
23. Lockhart A, Zelter M, Mensch-Dechene J, Antezana G, Paz-Zamora M, Vargas E & Coudert J (1976). Pressure-flow-volume relationships in pulmonary circulation of normal highlanders. J Appl Physiol 41, 449-456.
24. McLoughlin P & Keane M (2011). Physiological and pathophysiolgocial angiogenesis in the adult pulmonary circulation. In Comprehensive Physiology, vol. 1. pp. 1473-1508. Wiley Online Library (for the American Physiological Society).
25. 1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155, 606-616.
26. Meyrick B & Reid L (1983). Pulmonary hypertension. Anatomic and physiologic correlates. Clin Chest Med 4, 199-217.
27. Mulvany MJ (2012). Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol 110, 49-55.
28. Naeije R (2005). Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2, 20-22.
29. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF & Oka M (2005). Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171, 494-499.
30. Paddenberg R, Tiefenbach M, Faulhammer P, Goldenberg A, Gries B, Pfeil U, Lips KS, Piruat JI, Lopez-Barneo J, Schermuly RT, Weissmann N & Kummer W (2012). Mitochondrial complex II is essential for hypoxia-induced pulmonary vasoconstriction of intra- but not of pre-acinar arteries. Cardiovasc Res. 93, 702-710.
31. Penaloza D & Arias-Stella J (2007). The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 115, 1132-1146.
32. Perk K, Frei YF & Herz A (1964). Osmotic fragility of red blood cells of young and mature domestic and laboratory animals. Am J Vet Res 25, 1241-1248.
33. Rhodes J (2005). Comparative physiology of hypoxic pulmonary hypertension: historical clues from brisket disease. J Appl Physiol 98, 1092-1100.
34. Sands M, Howell K, Costello CM & McLoughlin P (2011). Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir Res 12, 17.
35. Sime F, Penaloza D & Ruiz L (1971). Bradycardia, increased cardiac output, and reversal of pulmonary hypertension in altitude natives living at sea level. Br Heart J 33, 647-657.
36. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83, 1325-1358.
37. Stenmark KR, Fagan KA & Frid MG (2006). Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99, 675-691.
38. Stenmark KR & McMurtry IF (2005). Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 97, 95-98.
39. Stenmark KR, Meyrick B, Galie N, Mooi WJ & McMurtry IF (2009). Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297, L1013-L1032.
40. Tawara S, Fukumoto Y & Shimokawa H (2007). Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 50, 195-200.
41. Tucker A, McMurtry IF, Reeves JT, Alexander AF, Will DH & Grover RF (1975). Lung vascular smooth muscle as a determinant of pulmonary hypertension at high altitude. Am J Physiol 228, 762-767.
42. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M & Narumiya S (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994.
43. Vock R & Weibel ER (1993). Massive hemorrhage causes changes in morphometric parameters of lung capillaries and concentration of leukocytes in microvasculature. Exp Lung Res 19, 559-577.
44. von Bethmann AN, Brasch F, Nusing R, Vogt K, Volk HD, Muller KM, Wendel A & Uhlig S (1998). Hyperventilation induces release of cytokines from perfused mouse lung. Am J Respir Crit Care Med 157, 263-272.
45. 2 supply through comparative physiology. Respir Physiol 118, 85-93.
46. Weibel ER, Federspiel WJ, Fryder-Doffey F, Hsia CC, König M, Stalder-Navarro V & Vock R (1993). Morphometric model for pulmonary diffusing capacity. I. Membrane diffusing capacity. Respir Physiol 93, 125-149.
47. Weimann J, Bloch KD, Takata M, Steudel W & Zapol WM (1999). Congenital NOS2 deficiency protects mice from LPS-induced hyporesponsiveness to inhaled nitric oxide. Anesthesiology 91, 1744-1753.
48. Weissmann N, Akkayagil E, Quanz K, Schermuly RT, Ghofrani HA, Fink L, Hanze J, Rose F, Seeger W & Grimminger F (2004). Basic features of hypoxic pulmonary vasoconstriction in mice. Respir Physiol Neurobiol 139, 191-202.
49. West JB (2004). The physiologic basis of high-altitude diseases. Ann Intern Med 141, 789-800.
50. Witzenrath M, Ahrens B, Kube SM, Hocke AC, Rosseau S, Hamelmann E, Suttorp N & Schutte H (2006). Allergic lung inflammation induces pulmonary vascular hyperresponsiveness. Eur Respir J 28, 370-377.
51. Yasuda T, Tada Y, Tanabe N, Tatsumi K & West J (2011). Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 301, L667-L674.
52. Yu L, Quinn DA, Garg HG & Hales CA (2008). Deficiency of the NHE1 gene prevents hypoxia-induced pulmonary hypertension and vascular remodeling. Am J Respir Crit Care Med 177, 1276-1284.